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Why the changes? 
 Cancers are slow 
 False positives are common 
 False positives are expensive 
 False positives are traumatic 
 Further testing can be dangerous 
 Rate of cancer growth may be slower than rate of 
natural aging 
Choosing Wisely 
 An initiative of the ABIM Foundation, Choosing Wisely is focused on 
encouraging physicians, patients and other health care stakeholders to 
think and talk about medical tests and procedures that may be 
unnecessary, and in some instances can cause harm. 
 To spark these conversations, leading specialty societies have created 
lists of “Things Physicians and Patients Should Question” — evidence-
based recommendations that should be discussed to help make wise 
decisions about the most appropriate care based on a patients’ 
individual situation. 
 Consumer Reports is developing and disseminating materials for 
patients through large consumer groups to help patients engage their 
physicians in these conversations and ask questions about what tests 
and procedures are right for them. 
 More than 50 specialty societies have now joined the campaign, and 
30+ societies will announce new lists in late 2013 and early 2014 
 

Consumer Reports March 2013 
 SAVE YOUR LIFE 
 3 Cancer tests you need 
 Cervical 
 Breast 
 Colon 
 8 Cancer tests to avoid 
 Prostate, Lung, Bladder, Ovary, Pancreas, Testicle, Oral, 
Skin 
Cervical cancer 
1. 19 year old college student wants to start birth 
control pills.  Menarche age 12, cycles regular, two 
male sexual partners so far, no history of gyn 
problems, never had a pap 
 
You should do a pap smear – yes/no 
 
Screening: Age < 21 
 Recommendation: Do not screen 
 Regardless of age of sexual initiation 
 
Screening: Age < 21 
 Rationale: 
 Cervical cancer is rare in women < 21 
 0.1% of all cancers (SEER data) 
 16 deaths occurred in US between 1992-2008 
 HPV infections are common 
 HPV related changes common on pap smear 
 Most lesions regress within 3 years 
 
 
Cervical cancer 
2. 24 year old about to get married, Normal cycles, no 
gyn problems currently (treated for chlamydia in 
college), 4 life time male partners, on BCP, had paps 
that were normal age 21 and 22, none last year. 
 
You should do a pap smear, using thin prep– yes/no 
Screening: Age 21-29 
Recommendation: 
 Begin screening at age 21 
 Methods and Interval 
 Screen with Cytology Alone 
 Every 3 years 
 HPV testing should not be used < age 30 yrs 
Screening: Age 21-29 
Screening Interval  
(years) 
Lifetime risk cervical cancer 
Cancers per 1000 women 
 
Lifetime risk death cervical cancer  
Deaths per 1000 women 
 
Colposcopies 
Per 1000 women 
1 3 0.03 2000 
2 4-6 0.05 1080 
3 5-8 0.05 760 
Rationale: 
CA Cancer J Clin 2012;62:154-155 
Cervical Cancer 
3. 36 year old woman divorced 2 years ago, last normal 
pap age 33, starting a new relationship and is 
considering IUD.   
 
You may offer HPV testing and pap to allow 5 year 
interval between future paps– yes/no 
Screening: Age 30-65 
 Recommendation: Methods and Interval 
 Co-testing every 5 years 
 Cytology alone every 3 years 
Cervical Cancer 
4. Widow age 62 is having her annual physical.  Has had 
paps faithfully every year with her well woman exams. 
Had total hysterectomy and BSO at age 48 for severe 
fibroids. 
 
You should advise her that current guidelines allow her 
to stop having paps but offer screening for vaginal 
cancer – yes/no 
Cervical Cancer 
5. Your patient age 67 heard that you can stop paps at age 
65.  She does not like them very much, has no 
symptoms, and hasn’t had a pa since age 60 since they 
were all normal. Not currently sexually active. 
 
You should recommend a pap -  yes/no 
Screening: Age > 65 
Recommendation:  
 Do not screen if adequate prior screening 
 Adequate prior screening 
 3 consecutive negative cytology results in 10 yrs 
 2 consecutive negative co-tests in 10 yrs 
 Most recent test within 5 yrs 
Summary:  Cervical Cancer Screening 
 Begin:   
 Age 21 
 Frequency  
 Age 21-29  
 Every 3 years cytology alone 
 No HPV testing 
 Age 30-65 
 Every 5 years co-testing  
 Every 3 years cytology alone 
 Recommend against annual screening in all patients 
Possible pap results 
 Negative for intraepithelial lesion or malignancy 
 Epithelial cell abnormalities 
 Squamous cells ASC-H,LSIL,HSIL 
 Squamous cell carcinoma 
 Glandular cell abnormalities 
 Atypical glandular cells 
 Atypical glandular cells, favor neoplastic 
 Endocervical adenocarcinoma in situ 
 Adenocarcinoma 
 
 Key 
 ASC-H = atypical squamous cells; cannot exclude a high-grade squamous 
intraepithelial lesion; ASC-US = atypical squamous cells of undetermined 
significance; HSIL = high-grade squamous intraepithelial lesion(s); LSIL = low-
grade squamous intraepithelial lesion(s). 
 
www.asccp.org/ConsensusGuidelines/UpdatedConsen
susGuidelinesAlgorithms/tabid/14410/Default.aspx 
Breast Cancer 
1. Your patient age 52 says that her mammogram last 
year was quite painful, and doesn’t want one this 
year.  She doesn’t think anything is wrong with her 
breasts but doesn’t check them much. 
 
You should strongly encourage her to have a 
mammogram every year per guidelines – yes/no 
Breast cancer 
2. Your patient age 39 reminds you that her mother 
passed away from breast cancer, as did mother’s 
sister.  BRCA testing was never done.  She has been a 
smoker most of her adult life.  She does not feel any 
abnormalities in the breast exams she has been 
doing since age 20. 
 
You should strongly encourage her to wait to age 50 to 
start mammograms – yes/no 
Breast cancer 
3. Your patient age 76 has had mammograms which have 
been normal every couple years but not very regularly.  
She doesn’t think she has any problems, and would like 
to stop having mammograms. 
 
You agree with her – yes/no 
Breast cancer recommendations 
                       age 40 - 49                         age 50+ 
 USPSTF -2009 – NO(grade C) 
 ACP-2007 – discuss 
 CTFPHC-2011 – discuss 
 not routine 
 ACS-2013 – annual with CE 
 Teach CE age 20 
 ACOG-2011 – annual w CE 
 Teach CE age 20 
 
 50 – 74  - biennial 
 50 
 50 – 69 – every 2 – 3 years 
 Less evidence 70-74 
 Annual – no end date 
 
 Annual  - no end date 
Breast cancer risk assessment tool 
 From National Cancer Institute 
 Based on history of breast cancer, age of menses, age of 
first born child, family history, BRCA mutation, any 
biopsies, any atypical hyperplasia, age, race/ethnicity 
Prostate cancer 
1. A 56 year old gentleman is having his annual exam 
and says his urination is a bit slowed up and he has 
nocturia times one.  He is otherwise pretty healthy 
though overweight. His rectal exam last year showed 
a large prostate and PSA was 3.8. 
 
You will miss points on your quality of care score if you 
do not do a rectal exam and PSA this year – yes/no 
 
 
Prostate Cancer  
 PSA?  
 DRE? 
 What a mess….. 
 
 
 WHY such indecisiveness and vague 
recommendations and conflict…… 
KEY Variables 
 PSA cut point – is 4.0 the best? 
 Interval – 1 year, 2 years, 4 years? 
 Screening by Symptoms – which ones? 
 Age/General health – age 40? 65? 
 Race  - same rules and risk for all races? 
 Family history – change the risk? 
 Type of treatment – which ones? 
 PSA cut off of 4 ? 
 
 
 15% have cancer  <   4   <  70 % false positive 
 15% aggressive 
 
 
Age related norms have been looked at 
 
Interval ? 
 The European study that showed benefit to screening 
used 2 – 4 year intervals 
 Tests of aggressive screening (more frequent and lower 
PSA) found more cancers but not more that “need” to 
be treated 
 
 Probably every 4 years is good enough, 2 years at a 
minimum 
Use Prostate Cancer Symptoms? 
 Trouble urinating 
 Decreased force in the stream of urine 
 Blood in the urine 
 Blood in the semen 
 General pain in the lower back, hips or thighs 
 Discomfort in the pelvic area 
 Bone pain 
 Erectile dysfunction 
 
Prostatitis symptoms 
 Pain or burning sensation when urinating (dysuria) 
 Difficulty urinating, such as dribbling or hesitant urination 
 Frequent urination, particularly at night (nocturia) 
 Urgent need to urinate 
 Pain in the abdomen, groin or lower back 
 Pain in the area between the scrotum and rectum 
(perineum) 
 Pain or discomfort of the penis or testicles 
 Painful orgasms (ejaculations) 
 Flu-like symptoms (with bacterial prostatitis) 
 
BPH symptoms 
 
 
 Weak urine stream 
 Difficulty starting urination 
 Stopping and starting while urinating 
 Dribbling at the end of urination 
 Frequent or urgent need to urinate 
 Increased frequency of urination at night (nocturia) 
 Straining while urinating 
 Not being able to completely empty the bladder 
 Urinary tract infection 
 Formation of stones in the bladder 
 Reduced kidney function 


Age to start and stop screening? 
 AUA consider screening at age 40 for +FH 
(father/brother), AA 
 Studies focused on age 55 – 69 – This is the “discussion 
with patient” age 
 Life expectancy 10 years or don’t screen 
 Stop at age 69 
Life expectancy of U.S. males 
 Age   Life expectancy 
 50    29.25 
 55    25.21 
 60    21.27 
 65    17.51 
 70    14.03 
 75    10.87   
Prostate Cancer Mortality varies 
with Gleason score 
 Of patients with Prostate Cancer, in the next 15 years…. 
 Low grade histology Gleason 2 – 4: 
  only 6/1000 person years will die from it 
 High grade histology Gleason 8-10: 
 121/1000 person years will die from it 
 
 Overall: 33/1000 person-years  per 15 years 
Guidelines for Special Groups? 
 African American – no large scale studies that offer 
useful guidelines 
 First degree relative (father or brother) with prostate 
cancer –additive risk 
 Worse if before age 65 
Incidence vs Death from.. 
USPSTF - 2012 
 Recommends against prostate cancer screening using 
PSA 
 
 
 
Prostate cancer 
2. Your patient is an African American male age 47 with 
no symptoms who wonders if he should have a PSA for 
the first time since his father died of prostate cancer 
when he was 56. 
 
You should defer PSA testing to age 50 – yes/no 
Other advice 
 AUA (2013) 
 Discuss at 40 for high risk 
 Discuss at 55 – 69 for all others 
 Stop age 70 or if life expectancy less than 10 – 15 
  2 year minimum interval,  if screening. 
 ACS (2010) recommends that asymptomatic men who have at 
least a 10-year life expectancy have an opportunity to make an 
informed decision with their health care provider about 
screening for prostate cancer after they receive information 
about the uncertainties, risks, and potential benefits 
associated with prostate cancer screening. 
 
Prostate cancer 
3. Your patient age 64 has severe CHF after 2 heart 
attacks (NYHA class 3 with EF 22%) and just found out 
he has multiple myeloma.  PSA’s have consistently 
been about 4.2, and he reminds you it is time to check 
again this year during his annual review. Urination 
stable. 
 
This would be a valuable addition to his careto likely 
help him live a bit longer – yes/no 
 
 
 
Summary for your patients 
 
 
 1000 men at age 60 -  NOT screened 
 23 men diagnosed with prostate cancer over 10 
years 
 4.4 will die over 10 years 
 
 1000 men  - screened at age 60 
 -115 biopsy because of abnormal PSA 
  -53 men diagnosed with prostate cancer  
  over 10 years 
-3.5 will die over 10 years 
  
  
  
  
  
 
The consequences of screening 
 100 – 120/1000 men screened have false positive – their 
biopsies were needless 
 –Biopsy causes worry and anxiety  - 100% 
 -Biopsy causes fever, infection, bleeding, urination 
problems, significant pain in 30% 
 -90% of men actually found to have CA chose 
treatment – which might not be needed: 
 29/1000 screened with erectile dysfunction 
 18/1000 men screened with urination problems 
 3/1000 screened -cardiac complications or PE 
Screening helps 
 Unscreened:  5/1000 men will die from prostate cancer 
after 10 years 
 
 Even  WITH screening, 4 – 5/1000 men WILL DIE 
FROM PROSTATE CANCER 
 
 With screening 1/1000 men will AVOID DEATH FROM 
PROSTATE CANCER 
 
Colon cancer  
1. Mr. Smith had a bad experience with his colonoscopy 
(the prep) when he was 62 and never wants to do 
that again. He has no bowel changes and feels well. 
 
You remind him that there are no other means of 
screening for colon cancer that have really been 
shown to save lives – yes/no 
 
 
 
 
Colon cancer screening 
 Just do it – ages 50 – 75 – everyone 
 Choices: 
 Colonoscopy every 10 
 Sigmoidoscopy every 5 with occult blood every 3 
 Annual fecal occult blood (HemoQuant hemoccult) 
 Barium Enema 
 
 Unproven yet: Fecal DNA, CT colonography 
Cost of Colon Cancer Screening 
 From healthcarebluebook.com 
 
 Colonoscopy - $1120         every 10 if normal 
 Flex Sig           - $740           every 5 with heme 
 Stool testing  - $5 – 25       every year 
 
Colon cancer 
2. Your patient is a remarkable fit gentleman of age 77, 
still rides his bicycle (with a helmet) and controls his 
BP with lisinopril 5 mg.  His dad lived to be 91, mother 
94. He wants a full physical. 
 
You tell him that screening for colon cancer at his age is 
a bad idea – yes/no 
Lung cancer 
1. Mr. Smith is 73 and quit smoking at age 65 when he 
retired after a pack a day history of smoking since age 
19. His breathing has come around pretty good, and 
his cough is gone.   
 
Screening for lung cancer by plain chest X-ray is better 
than CT – yes/no 
Lung Cancer 
 CT low dose should be offered annually to  
 high risk smokers 
 without symptoms of lung cancer  
 Age 55 – 80 
 1 pack a day for 30 years 
 Ex-smokers if quit in the last 15 years 
And the results will be… 
 1 in 100 screened will have possible lung cancer at a 
stage where early treatment helps 
 65 of 100 will be normal 
 25 of 100 will have nodules 
 More tests will probably be done over the next 2 years 
 10 of 100 will have other abnormalities noted 
 Infection, other damage 
 


Bladder Cancer 
 Insufficient evidence for screening  
 
 NO effect on mortality proven 
 Most cancers found without screening are curable 
 
 Risk factors:  Smoking, family history, workplace 
chemicals 
Ovarian Cancer 
 Do NOT screen 
 Annual screening with Transvaginal Ultrasound and 
CA-125 does not decrease ovarian cancer mortality 
 Bimanual palpation on pelvic exam is not considered a 
screening tool 
 
 BRAC1, 2,    Lynch Syndrome, 2 first degree relatives, 
Ashkenazi Jewish with 1 relative deserve special 
counseling 
  
 
 
Pancreatic Cancer 
 Do NOT screen population based 
 No evidence of effectiveness in reducing mortality 
 Poor tools 
 Low prevalence 
 Poor treatment 
 
Testicular Cancer 
 Do NOT Screen 
 90% of all testicle cancers will be cured, regardless of 
how they are found 
 Very low incidence 
Oral Cancer 
 Insufficient Evidence – not well studied 
 Mostly in Smokers 
 Worse in alcohol abusers PLUS smokers 
 Low incidence 
 
 
 Get a thorough dental exam every 6 months? 
Skin Cancer 
 Several types – basal cell, squamous cell, melanoma 
 Insufficient evidence to balance benefits and harms of 
whole body screening by patient or physician  
 High risk : Sun, >50 moles, family history, fair-skinned 
over 65 yrs old, atypical moles 
 
 Teach and follow A, B, C, D -  biopsy 
Questions? 
Sources 
 Choosing Wisely 
 AAFP 
 USPSTF 
 ACP Smart Medicine 

 
Screening for Cervical Cancer 
This topic page summarizes the U.S. Preventive Services Task Force 
(USPSTF) recommendations on screening for cervical cancer. 
Current Recommendation 
Release Date: March 2012 
 
 These recommendations apply to women who have a cervix, regardless of sexual history. These 
recommendations do not apply to women who have received a diagnosis of a high-grade 
precancerous cervical lesion or cervical cancer, women with in utero exposure to diethylstilbestrol, 
or women who are immunocompromised (such as those who are HIV positive). 
 The USPSTF recommends screening for cervical cancer in women ages 21 to 65 years with 
cytology (Pap smear) every 3 years or, for women ages 30 to 65 years who want to lengthen 
the screening interval, screening with a combination of cytology and human 
papillomavirus (HPV) testing every 5 years. See the Clinical Considerations for 
discussion of cytology method, HPV testing, and screening interval. 
Grade: A Recommendation. 
 The USPSTF recommends against screening for cervical cancer in women younger than 
age 21 years. 
Grade: D Recommendation. 
 The USPSTF recommends against screening for cervical cancer in women older than age 
65 years who have had adequate prior screening and are not otherwise at high risk for 
cervical cancer. See the Clinical Considerations for discussion of adequacy of prior 
screening and risk factors. 
Grade: D Recommendation. 
 The USPSTF recommends against screening for cervical cancer in women who have had a 
hysterectomy with removal of the cervix and who do not have a history of a high-grade 
precancerous lesion (i.e., cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical 
cancer.  
Grade: D Recommendation. 
 The USPSTF recommends against screening for cervical cancer with HPV testing, alone 
or in combination with cytology, in women younger than age 30 years. 
Grade: D Recommendation. 
 
